Researchers at the University of California, Los Angeles (UCLA), have developed a new type of allogeneic immune cell therapy that demonstrated potent antitumor activity against triple-negative breast cancer (TNBC) in preclinical studies.
Mutant KRAS is a well-known oncogenic driver and has remained undruggable for many decades. The development of pan-KRAS inhibitors that target a broad range of mutations is a promising approach to cancer treatment.
At the ongoing AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2025 in Boston, Bridgebio Oncology Therapeutics Inc. (BBOT) presented data on BBO-11818, a potent and selective KRAS inhibitor with activity against several KRAS mutants both in active (ON) and inactive (OFF) forms.
Adoptive cell therapy represents a major step forward in treating hematological cancers. Among its different approaches, chimeric antigen receptor natural killer (CAR-NK) cells are drawing growing interest.
During the first poster session of the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held in Boston, several presentations highlighted novel strategies that move beyond traditional antibody-drug conjugate (ADC) payloads and targets.
A technology that combines transcriptomic data and AI enables a novel approach to drug discovery based on the state of cells, how they behave and which genes they express. The Drugreflector model, developed by scientists at Cellarity Inc., learns from gene expression profiles and predicts which compounds could induce beneficial changes in that cellular state to develop a treatment.
Ipsen SA is expanding its cancer portfolio with the €1 billion (US$1.16 billion) acquisition of immuno-oncology specialist Imcheck SAS, and will pay €350 million up front with the balance to come in regulatory and sales-based milestones for the lead program ICT-01.
Expedition Medicines, which Flagship Pioneering Inc. has incubated for the past three years, came out of stealth mode with a $50 million commitment from Flagship to support Expedition’s platform technology to discover small molecules that covalently bind to their target.
Jiangsu Hengrui Pharmaceuticals Co. Ltd.; Shanghai Hengrui Pharmaceutical Co. Ltd. have synthesized antibody-drug conjugates (ADCs) comprising a claudin 6 (CLDN6)-targeting antibody linked to cytotoxic drug through linker. They are described as potentially useful for the treatment of ovarian cancer.
RSS
